Defining meaningful treatment outcomes in adults with spinal muscular atrophy: an expert consensus approach
14 affiliations
- 1Unidad de Enfermedades Neuromusculares, Hospital Universitari i Politècnic La Fe, IIS La Fe, CIBERER, University of Valencia
- 2Department of Neurology, Columbia University Irving Medical Center
- 3Adelphi Values PROVE
- 4Department of Neurology, Stanford University
- 5SMA Europe
- 6Department of Developmental Psychology, Tilburg University
- 7F. Hoffmann-La Roche Ltd
- 8Cure SMA
- 9Genentech, Inc.
- 10SMA Schweiz
- 11John Walton Muscular Dystrophy Research Centre, Newcastle University Translational and Clinical Research Institute
- 12Stan Cassidy Centre for Rehabilitation
- 13Department of Neurology, Friedrich Baur Institute, LMU University Hospital, LMU Munich
- 14Roche Products Ltd
Abstract
Introduction: Adults living with spinal muscular atrophy (SMA) are a heterogeneous population, with wide-ranging functional abilities and symptom severity. Currently, disease-modifying treatment effects are inconsistently measured in adult persons with SMA, which can impact access to treatment and quality of care. This study aims to identify, through expert consensus from healthcare professionals and patient advocacy group representatives, opinion on clinically meaningful treatment outcomes for adults with SMA.
Methods: A modified-Delphi study (two online survey rounds and a final consensus meeting) was conducted. The surveys captured key concepts of importance and aimed to understand constructs nearing consensus for discussion in the final meeting. Consensus was defined as ≥80% of panelists showing disagreement or agreement.
Results: Data were collected from neurologists, allied health professionals, and patient advocacy group representatives from across the United States and Europe (France, Germany, Italy, Spain, and the United Kingdom). Panelists reached consensus that the greatest needs for adults with SMA include greater independence and ability to perform activities of daily living, access to treatment that could preserve function and achieve disease stabilization, preservation of respiratory abilities for improved survival, and ensuring access to treatments and equipment. Panelists agreed that a meaningful treatment outcome should be defined by improvements in physical functioning, stabilization and maintenance in physical functioning, or any improvement in health-related quality of life. Consensus was reached that the definition of a meaningful treatment outcome depends on functional class, and that this definition evolves with disease progression. Panelists also agreed that disease stabilization is an important outcome across all key dimensions.
Discussion: Expert consensus was obtained on what constructs should be considered when determining meaningful treatment outcomes in adults with SMA, and how such outcomes should be interpreted. By establishing consensus on outcomes such as disease stabilization, this work supports a patient-centered approach to care. Our study highlights that relying on motor scales alone may not capture meaningful treatment benefit, particularly when stabilization in other outcomes are most relevant to adults with SMA. Our findings support shared decision-making, setting realistic and personalized therapeutic goals in clinical practice, and advocate for access to appropriate therapies and equipment.
Related
- Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who require permanent ventilation: a UK-based modified Delphi consensus process
- Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise
- Defining clinically meaningful pain reduction after spinal injections using an 11-point numerical rating scale and patient-reported relative reduction of pain
- Beyond motor rescue: defining adequate SMN restoration in spinal muscular atrophy.
- Defining Manuscript Peer Review: An International Delphi Consensus Study
BibTeX
@article{vazquezcosta2026defining,
title = {{Defining meaningful treatment outcomes in adults with spinal muscular atrophy: an expert consensus approach}},
author = {Juan F. Vázquez-Costa and Claudia A. Chiriboga and James Cochrane and Tina Duong and Yasemin Erbas and Cyrill Gasser and Jacqueline Glascock and Carol Jean Guittari and Nicole Gusset and Robert Muni Lofra and Colleen O’Connell and Danielle Riley and Louisa D. Townson and Maggie C. Walter and Kate Sully},
journal = {Frontiers in Neurology},
year = {2026},
month = nov,
doi = {10.3389/fneur.2026.1819127},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1819127/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Defining meaningful treatment outcomes in adults with spinal muscular atrophy: an expert consensus approach
AU - Juan F. Vázquez-Costa
AU - Claudia A. Chiriboga
AU - James Cochrane
AU - Tina Duong
AU - Yasemin Erbas
AU - Cyrill Gasser
AU - Jacqueline Glascock
AU - Carol Jean Guittari
AU - Nicole Gusset
AU - Robert Muni Lofra
AU - Colleen O’Connell
AU - Danielle Riley
AU - Louisa D. Townson
AU - Maggie C. Walter
AU - Kate Sully
PY - 2026
DA - 2026/11/03
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1819127
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1819127/full
AB - Introduction: Adults living with spinal muscular atrophy (SMA) are a heterogeneous population, with wide-ranging functional abilities and symptom severity. Currently, disease-modifying treatment effects are inconsistently measured in adult persons with SMA, which can impact access to treatment and quality of care. This study aims to identify, through expert consensus from healthcare professionals and patient advocacy group representatives, opinion on clinically meaningful treatment outcomes for adults with SMA. Methods: A modified-Delphi study (two online survey rounds and a final consensus meeting) was conducted. The surveys captured key concepts of importance and aimed to understand constructs nearing consensus for discussion in the final meeting. Consensus was defined as ≥80% of panelists showing disagreement or agreement. Results: Data were collected from neurologists, allied health professionals, and patient advocacy group representatives from across the United States and Europe (France, Germany, Italy, Spain, and the United Kingdom). Panelists reached consensus that the greatest needs for adults with SMA include greater independence and ability to perform activities of daily living, access to treatment that could preserve function and achieve disease stabilization, preservation of respiratory abilities for improved survival, and ensuring access to treatments and equipment. Panelists agreed that a meaningful treatment outcome should be defined by improvements in physical functioning, stabilization and maintenance in physical functioning, or any improvement in health-related quality of life. Consensus was reached that the definition of a meaningful treatment outcome depends on functional class, and that this definition evolves with disease progression. Panelists also agreed that disease stabilization is an important outcome across all key dimensions. Discussion: Expert consensus was obtained on what constructs should be considered when determining meaningful treatment outcomes in adults with SMA, and how such outcomes should be interpreted. By establishing consensus on outcomes such as disease stabilization, this work supports a patient-centered approach to care. Our study highlights that relying on motor scales alone may not capture meaningful treatment benefit, particularly when stabilization in other outcomes are most relevant to adults with SMA. Our findings support shared decision-making, setting realistic and personalized therapeutic goals in clinical practice, and advocate for access to appropriate therapies and equipment.
SN - 1664-2295
ER -